Losartan and azelastine either alone or in combination as modulators for endothelial dysfunction and platelets activation in diabetic hyperlipidemic rats.

Mohamed M ElseweidyGehad M ElnagarMarwa M ElsawyAbdelmoneim A AliNabila Zein

Published in: The Journal of pharmacy and pharmacology (2020)

Both drug categories may be expressed as suitable therapeutic tools for atherosclerotic complications either alone or along with other hypolipidemic drugs.

Keyphrases

small molecule
type diabetes
angiotensin ii
wound healing
drug induced
risk factors
adverse drug
emergency department
red blood cell